Qlife to present poster at PKU conference in the US
Olife will participate in the biennial National PKU Alliance, NPKUA, in Vancouver, Washington, USA on July 7-10, 2022, with a poster presentation as well as take part in a discussion panel on home monitoring of PHE levels.
The National PKU Alliance (NPKUA) is the largest event for the PKU community in the world and brings together patients, relatives, industry, and research partners every two years. This year, Qlife takes part in the conference, presenting a poster: “A Novel Home Monitoring Platform for Quantitative Determination of Phenylalanine in Phenylketonuria Patients”, and takes part in the discussion panel “When Can I Test Blood at Home? An Update on the Home Phe Monitor Panel
Discussion”. Julie Hindkaer, Assay Development, will be representing Qlife.
“Being present at NPKUA gives Qlife an opportunity to listen, learn and broaden our network as well as to present Egoo PHE test to the largest PKU community in the world”, says Thomas Warthoe, CEO of Qlife
Phenylketonuria, also called PKU, is a rare inherited disorder that causes an amino acid called phenylalanine to build up in the body. PKU is caused by a change in the phenylalanine hydroxylase (PAH) gene. This gene helps create the enzyme needed to break down phenylalanine.
Without the enzyme necessary to break down phenylalanine, a dangerous buildup can develop when a person with PKU eats foods that contain protein (phenylalanine source) or eats aspartame, an artificial sweetener. This can eventually lead to serious health problems.
The treatment is a lifelong diet. As first in the world, the Egoo PHE test makes it possible to monitor PHE (Phenylalanine) levels each day from home daily.